Merck Serono is finding its unconventional decision to opt for a strategic approach to the life sciences is sector yielding success.
Three years after starting a €40m fund ($60m), the corporate venturing unit of Germany-based pharmaceutical company Merck is finding its unconventional decision to opt for a strategic approach to the life sciences sector yielding success.
This approach sets Merck Serono Ventures apart from many of the best-known corporate venturing units in life sciences, such as GlaxoSmithKline’s SR One, which have opted for a largely return-based approach.
Roel Bulthuis, head of Merck Serono Ventures, said: "When we started the venture…
